Mene Pangalos, AstraZeneca EVP of BioPharmaceuticals R&D (AstraZeneca via YouTube)

In new deal, As­traZeneca places small bet on 'crit­i­cal but chal­leng­ing' tar­get

As­traZeneca has its eyes on NRF2 as a tar­get for in­flam­ma­to­ry and res­pi­ra­to­ry dis­eases, and it’s hand­ing out $2 mil­lion in cash to pluck a pre­clin­i­cal can­di­date from a drug dis­cov­ery shop.

It’s so ear­ly that C4X Dis­cov­ery doesn’t have a name for the oral NRF2 ac­ti­va­tor pro­gram just yet. In­clud­ing the up­front, the biotech is el­i­gi­ble for a to­tal of $16 mil­lion in pre­clin­i­cal pay­ments, af­ter which As­traZeneca will take over for clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion. Those fu­ture mile­stones add up to $385.8 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.